Beta-Band EEG Foretells Deep TMS Response in Treatment-Resistant OCD

A patient's resting beta rhythm, captured with routine scalp EEG, predicted whether deep transcranial magnetic stimulation (dTMS) would relieve obsessive-compulsive disorder symptoms in treatment-resistant cases, according to a study published ahead of print in Clinical EEG and Neuroscience.

The finding matters because obsessive-compulsive disorder affects 1.1 to 1.8 percent of the population, with adult females more likely to develop the condition, the authors note. For the subset of patients who do not respond to first-line medication and cognitive-behavioral therapy, dTMS delivers magnetic pulses through a coil designed to reach deeper cortical targets than conventional TMS.

What does beta rhythm tell clinicians?

Beta oscillations sit in the 13 to 30 hertz band on the EEG spectrum, the same rhythms clinicians see during focused attention and motor planning. The published study ties pre-treatment beta activity to dTMS outcome, framing the band as a candidate biomarker.

Such a marker could spare non-responders weeks of daily sessions and direct resources toward patients most likely to benefit. In the reading room, it would slot into the standard pre-treatment workup that already includes psychiatric rating scales, medication review, and structural imaging.

A quantitative EEG review adding a beta-band analysis could run alongside existing scalp recordings without extra electrodes or extended recording time. The addition would be operationally modest for most clinical neurophysiology services.

How does dTMS reach the dmPFC and ACC?

Deep transcranial magnetic stimulation uses a coil winding engineered to attenuate magnetic field decay, allowing pulses to penetrate beyond the superficial motor cortex. In the published protocol, the coil is positioned over the dorsomedial prefrontal cortex (dmPFC) and anterior cingulate cortex (ACC).

These are two midline structures long implicated in the cortico-striato-thalamo-cortical loops that drive obsessive thoughts and compulsive behaviors. The authors frame the mechanism as modulation of hyperactive frontal circuits through repeated stimulation sessions.

Treatment protocols in this field typically span several weeks of weekday sessions, though the precise schedule for the cohort under study will appear with the full paper.

What could this mean for treatment selection?

Treatment-resistant OCD carries a clinical burden that resists standard pharmacotherapy and behavioral therapy, leaving patients and clinicians with limited options. A pre-treatment EEG signature that stratifies candidates before the first dTMS session would change the consent conversation.

It would also change the case for payers who currently approve stimulation empirically. The study, however, arrives as an ahead-of-print manuscript, not as a regulatory submission, and clinicians should treat the beta-rhythm finding as a hypothesis to be replicated rather than a cleared decision rule.

In the monitoring unit, response to dTMS would still require the same follow-up clinical evaluation that accompanies any neuromodulation course. The difference is that the pre-treatment baseline would now carry an explicit beta-band annotation, framing the entire treatment arc as a before-and-after comparison rather than a blind initiation.

The journal's forthcoming issue will clarify cohort size, blinded outcome assessment, and the predictive accuracy the abstract does not yet specify. For the EEG laboratory, the practical next step is straightforward.

Quantitative analysis pipelines already extract band power from standard recordings, and most modern review software reports a beta-band summary by default. The technical threshold for adding such a report to a pre-dTMS consultation is low, even if the clinical threshold for acting on it remains undefined.

Whether the resulting report changes the clinical decision is the question the full publication, and the replication studies that follow it, will need to answer in the years ahead.